Global Influenza Medication Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Influenza Medication Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global Influenza Medication market finds that the global Influenza Medication market reached a value of USD 4185.04 million in 2022. It’s expected that the market will achieve USD 6536.88 million by 2028, exhibiting a CAGR of 7.72% during the forecast period.

Market Drivers

According to statistics released by the Centers for Disease Control and Prevention, an estimated 48.8 million people are infected with the flu. Of these, 959,000 were hospitalized and 79,400 died of the influenza virus. Between 2017 and 2018, the highest mortality rate observed in patients over the age of 65 in the United States was approximately 68,448. The epidemic of influenza disease and increasing demand for clinical treatments and new therapies are driving significant growth in the Influenza Medication market.
In addition, the accelerated demand for treatments and new therapies, as well as increasing awareness of treatments and technological advances, have also driven market growth.
In 2018, North America and Europe accounted for the largest share of the influenza drug market, followed by Asia, Latin America, and the Middle East and Africa. The United States dominates the North American Influenza Medication market, Europe accounting for approximately 39.35% of the market in 2018. As the adoption of advanced and high-cost drug therapies continues to increase, treatment rates increase, and the country's preferential reimbursement policy. It is expected that from 2019 to 2025, Europe and the Asia-Pacific region will be lucrative markets. The number of public awareness programs for the prevention and diagnosis of chronic diseases such as influenza has greatly reduced influenza in Europe. In Europe, demand for influenza drug products is greatest, with a large share in the inosine product sector. The Asia-Pacific region is expected to dominate the global market due to the significant contributions of developing countries. China and India are densely populated countries with the largest number of influenza patients, which makes them the main driving force for market growth in the Asia-Pacific region. Due to the significant contributions of developing countries. China and India are densely populated countries with the largest number of influenza patients, which makes them the main driving force for market growth in the Asia-Pacific region. Due to the significant contributions of developing countries. China and India are densely populated countries with the largest number of influenza patients, which makes them the main driving force for market growth in the Asia-Pacific region.

Region Overview:

From 2023-2028, China is estimated to witness robust growth prospects.

Company Overview:

The top three companies are Roche, GSK, Guangdong HEC Pharmaceutical Co., Ltd with the revenue market share of 24.07%, 19.96% and 6.77% in 2018.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

GlaxoSmithKline plc is a British multinational pharmaceutical company headquartered in Brentford, London. GlaxoSmithKline plc has 3 global businesses that research, develop and manufacture innovative pharmaceutical, vaccine and consumer health products.

Segmentation Overview:

Among different product types, Zanamivir segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Adult segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Influenza Medication market covered in Chapter 3:

GSK
AstraZeneca
Pharmstandard OJSC
Guangdong HEC Pharmaceutical Co., Ltd
Pfizer
BioCryst Pharmaceuticals
Roche
Daiichi Sankyo Company
Alvogen Inc.

In Chapter 4 and Chapter 14.2, on the basis of types, the Influenza Medication market from 2018 to 2029 is primarily split into:

Zanamivir
Oseltamivir phosphate
Peramivir
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Influenza Medication market from 2018 to 2029 covers:

Adult
Kids

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)